Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Xiaomi Shares Jump on Europe EV Expansion Plan 
U.S. Issues Cuba Health Alert as Illnesses Rise 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Add as a preferred source on Google
AstraZeneca has discontinued a late-stage clinical trial evaluating volrustomig combined with chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC), dealing another setback to the pharmaceutical giant’s drug development pipeline.
The company said Monday that it stopped the Phase III eVOLVE-Lung02 trial following a recommendation from an independent data monitoring committee. The committee concluded that the volrustomig combination was unlikely to achieve the study’s primary endpoints of improving progression-free survival (PFS) or overall survival (OS).
The trial focused on patients whose tumors lacked PD-L1 expression and compared the experimental treatment with the study’s control arm.
Despite the disappointing efficacy findings, AstraZeneca reported no unexpected safety issues. The safety profile observed with volrustomig and chemotherapy remained consistent with the known profiles of the individual treatments, with no new safety concerns identified.
Susan Galbraith, AstraZeneca’s executive vice president of oncology hematology research and development, acknowledged the disappointing outcome while emphasizing that the company intends to apply lessons from the study to its ongoing efforts to develop new lung cancer treatments.
eVOLVE-Lung02 was a large global study involving 895 patients across 25 countries, highlighting the scale of AstraZeneca’s investment in testing volrustomig as a potential treatment for metastatic NSCLC.
The trial discontinuation adds to investor scrutiny of the AstraZeneca drug pipeline following several clinical setbacks this year. The company is pursuing an ambitious target of reaching $80 billion in annual revenue, making the performance of its late-stage pipeline increasingly important to its long-term growth strategy.
Another notable setback involved Wainua, developed with Ionis Pharmaceuticals. Earlier this year, results from the Phase III CARDIO-TTRansform study showed that the treatment failed to outperform placebo in reducing cardiovascular deaths among patients with a progressive and potentially fatal heart condition.
The latest failure underscores the uncertainty surrounding late-stage pharmaceutical development, even as AstraZeneca continues investing heavily in oncology, cardiovascular disease and rare-disease therapies.
